Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
149.8 EUR | -1.09% | -2.12% | -4.89% |
Apr. 24 | IMCD's Spanish Unit to Buy Cobapharma | MT |
Mar. 27 | IMCD's Benelux Arm to Purchase Gova Ingredients | MT |
Sales 2024 * | 4.78B 5.12B | Sales 2025 * | 5.08B 5.44B | Capitalization | 8.62B 9.24B |
---|---|---|---|---|---|
Net income 2024 * | 296M 317M | Net income 2025 * | 334M 358M | EV / Sales 2024 * | 2.05 x |
Net Debt 2024 * | 1.18B 1.26B | Net Debt 2025 * | 954M 1.02B | EV / Sales 2025 * | 1.89 x |
P/E ratio 2024 * |
29.4
x | P/E ratio 2025 * |
26.6
x | Employees | - |
Yield 2024 * |
1.45% | Yield 2025 * |
1.56% | Free-Float | 98.13% |
Latest transcript on IMCD N.V.
1 day | -1.85% | ||
1 week | -0.88% | ||
Current month | -7.25% | ||
1 month | -9.61% | ||
3 months | +6.65% | ||
6 months | +33.30% | ||
Current year | -3.84% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 52 | 20-06-29 | |
Hans Kooijmans
DFI | Director of Finance/CFO | 63 | 11-02-28 |
Marcus Jordan
COO | Chief Operating Officer | 50 | 97-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 18-05-08 | |
Amy Motto
BRD | Director/Board Member | 52 | 20-06-29 |
Willem Eelman
BRD | Director/Board Member | 60 | 22-05-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.06% | 303 M€ | +11.29% | ||
0.37% | 18 M€ | +3.04% | - | |
0.21% | 2 M€ | +8.60% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 149.8 | -1.09% | 53 673 |
24-04-24 | 151.5 | -1.85% | 152,814 |
24-04-23 | 154.4 | +1.88% | 115,921 |
24-04-22 | 151.5 | +0.17% | 77,364 |
24-04-19 | 151.2 | -1.21% | 130,416 |
Real-time Euronext Amsterdam, April 24, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.84% | 9.21B | |
+27.66% | 1.02B | |
+10.07% | 176M | |
+38.36% | 144M | |
+6.14% | 117M | |
-2.44% | 101M | |
+6.50% | 86.56M |
- Stock Market
- Equities
- IMCD Stock